
|Articles|February 27, 2014 (Updated: April 18, 2020)
- NSCLC (Issue 2)
- Volume 2
- Issue 1
Crizotinib Resistance in ALK-Positive Lung Cancer
Author(s)Alice T. Shaw, MD, PhD
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses resistance to crizotinib in patients with ALK-positive lung cancer.
Learn more about thetreatment of ALK-positive lung cancer > >
Articles in this issue
about 12 years ago
Clinical Update: ALK-Positive NSCLCabout 12 years ago
PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancerabout 12 years ago
Treating Older Patients With NSCLCabout 12 years ago
Treatment of Elderly Patients With NSCLCabout 12 years ago
Current Challenges in Molecular Testing in NSCLCabout 12 years ago
Individualized Maintenance Therapy for NSCLCabout 12 years ago
Frontline Treatment Considerations in Non-Small Cell Lung Cancer






























